¿Cuáles son las fases aguda, subaguda y crónica del ACV isquémico?
Describeme las características de los estadíos agudo, subagudo y crónico de una persona con ACV isquémico
Summary
I will describe key clinical and neuroimaging characteristics of acute, subacute, and chronic phases after an ischemic stroke, focusing on what typically happens in each time window and how it appears clinically and on imaging. Time cutoffs vary slightly among sources; they are practical rather than absolute biological boundaries. The evolution in each phase has implications for diagnosis, acute treatment (reperfusion), secondary prevention, and rehabilitation.
1. Time windows: practical definitions
Different guidelines and reviews use slightly different terminology, but a common, clinically useful division is: [1]
- Hyperacute: first hours (0–24 h), especially 0–4.5 h (IV thrombolysis window) and up to 24 h for endovascular therapy in selected cases.
- Acute: from symptom onset to ~7 days.
- Subacute: ~1–4 weeks after stroke.
- Chronic: from ~3 months onward.
The question often groups hyperacute + early acute simply as “acute,” then subacute and chronic. Pathophysiology and imaging evolve continuously; the “boundaries” are approximations.
2. Acute phase of ischemic stroke
2.1. Time frame and pathophysiology
- Approximate time frame: onset to ~7 days.
- Pathophysiology:
- Vascular occlusion → sudden reduction of cerebral blood flow.
- Ischemic core (irreversibly injured tissue) surrounded by penumbra, hypoperfused but potentially salvageable tissue.
- Cytotoxic edema predominates early (cell swelling, restricted diffusion).
- Risk of hemorrhagic transformation is highest in this phase, especially after reperfusion therapy or large infarcts. [1]
2.2. Clinical characteristics
- Abrupt onset of focal neurological deficit, typically maximal at onset (or rapidly progressive over minutes), e.g.:
- Hemiparesis, hemisensory loss.
- Aphasia or dysarthria.
- Visual field defects (hemianopia).
- Neglect, gaze deviation.
- Ataxia, vertigo, diplopia in posterior circulation strokes.
- Possible fluctuation or progression in the first hours (evolving stroke), particularly in large-vessel occlusion or when collateral flow is unstable.
- Altered consciousness can occur in large hemispheric or brainstem strokes.
- Frequent systemic manifestations:
- Elevated blood pressure, stress hyperglycemia.
- Fever (infections, aspiration) and cardiac arrhythmias (e.g., atrial fibrillation).
- High risk of early complications: cerebral edema with mass effect, increased intracranial pressure, malignant MCA infarction, early seizures, aspiration pneumonia, DVT/PE. [1]
2.3. Imaging characteristics (acute)
CT (non-contrast) – first hours/days:
- Often normal in the first hours.
- Early signs:
- Subtle hypodensity, loss of gray–white differentiation.
- Insular ribbon sign, obscuration of lentiform nucleus.
- Hyperdense artery sign (e.g., MCA), indicating intraluminal thrombus.
- Over 24–72 h, infarct becomes more clearly hypodense with edema and possible mass effect (sulcal effacement, midline shift). [2]
MRI (especially DWI):
- DWI hyperintensity with low ADC in minutes to hours → hallmark of acute ischemia due to cytotoxic edema.
- T2/FLAIR may be normal in very early hours, then becomes hyperintense as edema develops.
- Perfusion imaging (CT or MR) shows mismatch between perfusion and diffusion (penumbra vs core). [2]
Angiographic imaging (CTA/MRA):
- Identification of arterial occlusion (large vessel occlusion) and vascular anatomy.
- Crucial for acute reperfusion decisions (thrombolysis, thrombectomy). [1]
3. Subacute phase of ischemic stroke
3.1. Time frame and pathophysiology
- Approximate time frame: ~1–4 weeks from stroke onset (some authors extend to 6 weeks).
- Pathophysiology:
- Edema begins to peak around days 3–5 and then gradually resolves.
- Inflammatory and reparative processes (microglial activation, astrocytosis, angiogenesis, axonal sprouting).
- Evolution from cytotoxic edema toward vasogenic edema and then tissue liquefaction. [3]
3.2. Clinical characteristics
- Deficits are already established; neurologic status tends to stabilize with possible early recovery:
- Some improvement from resolution of edema and reperfusion of penumbra.
- Still, significant disability often persists.
- Risk of neurological worsening in the early subacute period, mainly due to:
- Cerebral edema and mass effect in large infarcts (especially first week).
- Hemorrhagic transformation.
- Complications such as infections, arrhythmias, DVT/PE.
- Early rehabilitation typically starts in this phase: mobilization, prevention of complications (contractures, pressure ulcers), and functional training. [4]
- Transition towards subacute complications: spasticity, shoulder pain, depression, dysphagia, cognitive problems, fatigue.
3.3. Imaging characteristics (subacute)
CT:
- Infarct becomes more well-defined hypodense area.
- Edema and mass effect may still be present but typically start to decrease after ~1 week.
- Hemorrhagic transformation (if present) is visible as hyperdense components within the infarct. [2]
MRI:
- DWI signal may remain hyperintense for ~1–2 weeks but ADC values gradually pseudo-normalize around 1 week and later become increased (reflecting chronic changes).
- FLAIR/T2: persistent hyperintensity with evolving volume and borders.
- Gadolinium enhancement may appear due to blood–brain barrier disruption in the subacute stage.
- Overall, the lesion edges become clearer as infarct organization progresses. [3]
4. Chronic phase of ischemic stroke
4.1. Time frame and pathophysiology
- Approximate time frame: from ~3 months onward (many structural changes established by 3–6 months).
- Pathophysiology:
- Resolution of acute/subacute edema.
- Permanent tissue loss with encephalomalacia (softening/liquefactive necrosis) and gliosis.
- Wallerian degeneration in affected tracts (e.g., corticospinal tract).
- Functional reorganization and neuroplasticity in surrounding and contralateral brain regions. [3]
4.2. Clinical characteristics
- Deficits become relatively stable, with a combination of:
- Residual motor, sensory, language, visual, or cognitive deficits, depending on lesion location and severity.
- Partial or substantial recovery in many patients, especially with rehabilitation and younger age.
- Chronic manifestations and complications may include:
- Spasticity, contractures, pain syndromes (e.g., central post-stroke pain), shoulder subluxation.
- Epileptic seizures and post-stroke epilepsy.
- Cognitive impairment or vascular dementia, mood disorders (depression, anxiety), fatigue.
- Gait impairment, falls, dysphagia with chronic aspiration risk. [5]
- Focus shifts to:
- Secondary prevention (antithrombotic therapy, risk factor control, management of AF, carotid disease).
- Long-term rehabilitation and community reintegration.
4.3. Imaging characteristics (chronic)
CT:
- Infarcted area appears as well-demarcated hypodensity with volume loss.
- Encephalomalacic changes:
- Ex vacuo dilatation of adjacent ventricles and sulcal enlargement.
- No significant mass effect; often mild negative mass effect (local atrophy). [2]
MRI:
- T1: hypointense in the region of tissue loss.
- T2/FLAIR:
- Hyperintense gliotic rim; central CSF-like signal if cavity has formed.
- Reduced volume/atrophy in affected territory.
- DWI is usually normal or may show only mild chronic changes; no restricted diffusion.
- Wallerian degeneration may appear as signal change and atrophy along white matter tracts (e.g., internal capsule, cerebral peduncle). [3]
5. Clinical implications across phases
-
Acute phase:
- Goal: rapid diagnosis and reperfusion therapy when indicated (IV thrombolysis, mechanical thrombectomy), stabilization of vital functions, prevention of early complications.
- Imaging aimed at excluding hemorrhage, identifying ischemia and vessel occlusion, and estimating core vs penumbra. [1]
-
Subacute phase:
- Goal: begin early rehabilitation, prevent secondary complications, refine stroke etiology workup (e.g., cardiac monitoring, vascular imaging), start appropriate secondary prevention. [4]
-
Chronic phase:
- Goal: long-term functional optimization, treatment of chronic sequelae (spasticity, pain, mood disorders, seizures), and strict vascular risk factor control to prevent recurrence and progression of vascular cognitive impairment. [5]
If you want, I can summarize the key differentiating features in a very compact table (time window, clinical picture, CT/MRI findings) for quick teaching use.
Fuentes
- https://www.ahajournals.org/doi/10.1161/STR.0000000000000375
- https://www.ahajournals.org/doi/10.1161/STR.0000000000000152
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2868719
- https://www.ahajournals.org/doi/10.1161/STR.0000000000000183
- https://www.ahajournals.org/doi/10.1161/STR.0000000000000158
Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.